Literature DB >> 30587590

IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses.

Rosa M Santana Carrero1,2, Figen Beceren-Braun2, Sarai C Rivas2, Shweta M Hegde2, Achintyan Gangadharan2, Devin Plote2,3, Gabriel Pham2, Scott M Anthony1,2, Kimberly S Schluns4,2.   

Abstract

Previous studies have provided evidence that IL-15 expression within human tumors is crucial for optimal antitumor responses; however, the regulation of IL-15 within the tumor microenvironment (TME) is unclear. We report herein, in analyses of mice implanted with various tumor cell lines, soluble IL-15/IL-15Rα complexes (sIL-15 complexes) are abundant in the interstitial fluid of tumors with expression preceding the infiltration of tumor-infiltrating lymphocytes. Moreover, IL-15 as well as type I IFN, which regulates IL-15, was required for establishing normal numbers of CD8 T cells and natural killer cells in tumors. Depending on tumor type, both the tumor and the stroma are sources of sIL-15 complexes. In analyses of IL-15 reporter mice, most myeloid cells in the TME express IL-15 with CD11b+Ly6Chi cells being the most abundant, indicating there is a large source of IL-15 protein in tumors that lies sequestered within the tumor stroma. Despite the abundance of IL-15-expressing cells, the relative levels of sIL-15 complexes are low in advanced tumors but can be up-regulated by local stimulator of IFN genes (STING) activation. Furthermore, while treatment of tumors with STING agonists leads to tumor regression, optimal STING-mediated immunity and regression of distant secondary tumors required IL-15 expression. Overall, our study reveals the dynamic regulation of IL-15 in the TME and its importance in antitumor immunity. These findings provide insight into an unappreciated attribute of the tumor landscape that contributes to antitumor immunity, which can be manipulated therapeutically to enhance antitumor responses.

Entities:  

Keywords:  CD8 T cells; interferons; interleukin 15; myeloid cells; tumors

Mesh:

Substances:

Year:  2018        PMID: 30587590      PMCID: PMC6329954          DOI: 10.1073/pnas.1814642116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

3.  The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides.

Authors:  John-Demian Sauer; Katia Sotelo-Troha; Jakob von Moltke; Kathryn M Monroe; Chris S Rae; Sky W Brubaker; Mamoru Hyodo; Yoshihiro Hayakawa; Joshua J Woodward; Daniel A Portnoy; Russell E Vance
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

4.  Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets.

Authors:  Erwan Mortier; Rommel Advincula; Leesun Kim; Stephen Chmura; Julio Barrera; Boris Reizis; Barbara A Malynn; Averil Ma
Journal:  Immunity       Date:  2009-11-12       Impact factor: 31.745

5.  IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells.

Authors:  Ping Yu; Richard N Bamford; Thomas A Waldmann
Journal:  Eur J Immunol       Date:  2014-11       Impact factor: 5.532

6.  Intestinal epithelial cells both express and respond to interleukin 15.

Authors:  H C Reinecker; R P MacDermott; S Mirau; A Dignass; D K Podolsky
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

7.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Authors:  Leticia Corrales; Laura Hix Glickman; Sarah M McWhirter; David B Kanne; Kelsey E Sivick; George E Katibah; Seng-Ryong Woo; Edward Lemmens; Tamara Banda; Justin J Leong; Ken Metchette; Thomas W Dubensky; Thomas F Gajewski
Journal:  Cell Rep       Date:  2015-05-07       Impact factor: 9.423

8.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.

Authors:  J P Lodolce; D L Boone; S Chai; R E Swain; T Dassopoulos; S Trettin; A Ma
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

Review 9.  The role of myeloid cells in cancer therapies.

Authors:  Camilla Engblom; Christina Pfirschke; Mikael J Pittet
Journal:  Nat Rev Cancer       Date:  2016-07       Impact factor: 60.716

10.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.

Authors:  Mercedes B Fuertes; Aalok K Kacha; Justin Kline; Seng-Ryong Woo; David M Kranz; Kenneth M Murphy; Thomas F Gajewski
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

View more
  39 in total

Review 1.  Control of memory CD8+ T cell longevity and effector functions by IL-15.

Authors:  Jeffrey C Nolz; Martin J Richer
Journal:  Mol Immunol       Date:  2019-12-06       Impact factor: 4.407

2.  Cutting Edge: Inhibition of the Interaction of NK Inhibitory Receptors with MHC Class I Augments Antiviral and Antitumor Immunity.

Authors:  Abir K Panda; Arunakumar Gangaplara; Maja Buszko; Kannan Natarajan; Lisa F Boyd; Suveena Sharma; David H Margulies; Ethan M Shevach
Journal:  J Immunol       Date:  2020-06-29       Impact factor: 5.422

Review 3.  The cancer-natural killer cell immunity cycle.

Authors:  Nicholas D Huntington; Joseph Cursons; Jai Rautela
Journal:  Nat Rev Cancer       Date:  2020-06-24       Impact factor: 60.716

4.  Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity.

Authors:  Jingya Guo; Yong Liang; Diyuan Xue; Jiao Shen; Yueqi Cai; Jiankun Zhu; Yang-Xin Fu; Hua Peng
Journal:  Cell Res       Date:  2021-08-10       Impact factor: 25.617

5.  NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.

Authors:  Tanya O Robinson; Shweta M Hegde; Allison Chang; Achintyan Gangadharan; Sarai Rivas; Loui Madakamutil; Jonathan Zalevsky; Takahiro Miyazaki; Kimberly S Schluns
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

6.  Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.

Authors:  Armin Mahmoud Salehi Kheshti; Farnaz Hajizadeh; Asal Barshidi; Bentolhoda Rashidi; Farbod Ebrahimi; Simin Bahmanpour; Vahid Karpisheh; Fatemeh Karimian Noukabadi; Fariba Karoon Kiani; Hadi Hassannia; Fatemeh Atyabi; Seyed Hossein Kiaie; Fatah Kashanchi; Jamshid Gholizadeh Navashenaq; Hamed Mohammadi; Rafieh Bagherifar; Reza Jafari; Naime Majidi Zolbanin; Farhad Jadidi-Niaragh
Journal:  Pharm Res       Date:  2022-02-15       Impact factor: 4.200

7.  Tumor cell-expressed IL-15Rα drives antagonistic effects on the progression and immune control of gastric cancer and is epigenetically regulated in EBV-positive gastric cancer.

Authors:  Jing Wei; Chen Guo; Xiang An; Wenxuan Miao; Chenli Zhang; Binsheng Wang; Wei Cai; Min Li; Fangfang Zhang
Journal:  Cell Oncol (Dordr)       Date:  2020-08-07       Impact factor: 6.730

Review 8.  Interleukins in cancer: from biology to therapy.

Authors:  Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold
Journal:  Nat Rev Cancer       Date:  2021-06-03       Impact factor: 69.800

Review 9.  Intratumoural administration and tumour tissue targeting of cancer immunotherapies.

Authors:  Ignacio Melero; Eduardo Castanon; Maite Alvarez; Stephane Champiat; Aurelien Marabelle
Journal:  Nat Rev Clin Oncol       Date:  2021-05-18       Impact factor: 66.675

10.  Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis.

Authors:  Laura Ducimetière; Giulia Lucchiari; Gioana Litscher; Marc Nater; Laura Heeb; Nicolás Gonzalo Nuñez; Laura Wyss; Dominik Burri; Marijne Vermeer; Julia Gschwend; Andreas E Moor; Burkhard Becher; Maries van den Broek; Sonia Tugues
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.